Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.

@article{Rog2007OromucosalDF,
  title={Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.},
  author={David Rog and Turo J. Nurmikko and Carolyn A. Young},
  journal={Clinical therapeutics},
  year={2007},
  volume={29 9},
  pages={
          2068-79
        }
}
BACKGROUND Central neuropathic pain (CNP), pain initiated or caused by a primary lesion or dysfunction of the central nervous system, occurs in ~28% of patients with multiple sclerosis (MS). Delta(9)-Tetrahydrocannabinol/cannabidiol (THC/CBD), an endocannabinoid system modulator, has demonstrated efficacy for up to 4 weeks in randomized controlled trials in the treatment of CNP in patients with MS. OBJECTIVE The purpose of this extension was to establish long-term tolerability and… Expand
Tetrahydrocannabinol (Delta 9-THC) Treatment in Chronic Central Neuropathic Pain and Fibromyalgia Patients: Results of a Multicenter Survey
TLDR
Delta 9-THC treatment as part of a broader pain management plan therefore may represent a promising coanalgesic therapeutic option for the treatment of chronic pain in central neuropathy and fibromyalgia. Expand
Pain Modulation after Oromucosal Cannabinoid Spray (SATIVEX®) in Patients with Multiple Sclerosis: A Study with Quantitative Sensory Testing and Laser-Evoked Potentials
TLDR
The results indicate that Sativex® therapy provides pain relief in MS patients and suggest that it might modulate peripheral cold-sensitive TRP channels. Expand
A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis
TLDR
The results of the first phase III placebo-controlled study of the efficacy of the endocannabinoid system modulator delta-9-tetrahydrocannabinol (THC)/cannabidiol (CBD) oromucosal spray to alleviate central neuropathic pain suggest that further studies are required to explore the full potential of THC/CBD spray in these patients. Expand
A multicentre, open-label, follow-on study to assess the long-term maintenance of effect, tolerance and safety of THC/CBD oromucosal spray in the management of neuropathic pain
TLDR
In this previously difficult to manage patient population, THC/CBD spray was beneficial for the majority of patients with PNP associated with diabetes or allodynia. Expand
Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis
TLDR
No new safety concerns were identified with chronic Sativex treatment, and serious AEs were uncommon, and patients who remained in the study reported continued benefit. Expand
Dronabinol Is a Safe Long-Term Treatment Option for Neuropathic Pain Patients
TLDR
The trial results demonstrate that dronabinol is a safe long-term treatment option and a positive benefit-risk ratio and no signs of drug abuse and only one possible case of dependency occurred. Expand
Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis
TLDR
Clinical studies on cannabis-based medicine extract (CBME), in particular nabiximols, in spasticity, as well as pain, and bladder dysfunction in MS are analyzed. Expand
THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis
TLDR
Initial well-controlled studies with Sativex oromucosal spray administered as an add-on to usual therapy have produced promising results and highlight encouraging avenues for future research. Expand
Role of Cannabinoids in the Treatment of Pain and (Painful) Spasticity
TLDR
Patients with unsatisfactory response to other methods of pain therapy and who were characterized by failed stress adaptation particularly benefited from treatment with cannabinoids, but none of the attempts to overcome the disadvantage of the narrow therapeutic index have resulted in a major breakthrough. Expand
An Open‐Label Comparison of Nabilone and Gabapentin as Adjuvant Therapy or Monotherapy in the Management of Neuropathic Pain in Patients with Peripheral Neuropathy
  • J. Bestard, C. Toth
  • Medicine
  • Pain practice : the official journal of World Institute of Pain
  • 2011
TLDR
The benefits of monotherapy or adjuvant therapy with nabilone appear comparable to gabapentin for management of NeP, and sleep adequacy and the sleep problems index within the MOSSS improved in nabil one monotherapy patients in particular. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 28 REFERENCES
Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis
TLDR
CBM was generally well tolerated, although more patients on CBM than placebo reported dizziness, dry mouth, and somnolence, and Cognitive side effects were limited to long-term memory storage. Expand
Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up
TLDR
These data provide limited evidence for a longer term treatment effect of cannabinoids in multiple sclerosis, and a long term placebo controlled study is now needed to establish whether cannabinoids may have a role beyond symptom amelioration in MS. Expand
Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial
TLDR
Dronabinol has a modest but clinically relevantanalgesic effect on central pain in patients with multiple sclerosis and on the SF-36 quality of life scale, the two items bodily pain and mental health indicated benefits from active treatment compared with placebo. Expand
Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial.
TLDR
Gabapentin is effective in the treatment of pain and sleep interference associated with PHN and Mood and quality of life also improve with gabapentin therapy. Expand
Antiepileptic medications in multiple sclerosis: adverse effects in a three-year follow-up study
TLDR
A significantly higher incidence of adverse effects in patients treated with CBZ is found, with a high rate of discontinuation at low dosages and episodes of evident worsening of neurological functioning compared to GBP or LMT. Expand
Lamotrigine adjunctive therapy in painful phenomena in MS: Preliminary observations
TLDR
Lamotrigine (LTG), a new antiepileptic drug, has been found to be effective against the paroxysmal pain of trigeminal neuralgia, and this open add-on study assessed whether LTG could also improve burning paresthesias, pain, and PTS in MS patients who were not responding to maximum doses of drugs that are usually effective. Expand
EFNS guidelines on pharmacological treatment of neuropathic pain
TLDR
Evaluated trials provide level A evidence for the efficacy of tricyclic antidepressants, gabapentin, pregabalin and opioids, with a large number of class I trials, followed by topical lidocaine and the newer antidepressants venlafaxine and duloxetine. Expand
Algorithm for neuropathic pain treatment: An evidence based proposal
TLDR
NNT and NNH are currently the best way to assess relative efficacy and safety, but the need for dichotomous data, which may have to be estimated retrospectively for old trials, and the methodological complexity of pooling data from small cross‐over and large parallel group trials, remain as limitations. Expand
Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study
TLDR
The role of gabapentin as an efficacious and well‐tolerated treatment for postherpetic neuralgia is confirmed and the most common adverse events were dizziness and somnolence, particularly during the titration phase. Expand
Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial.
TLDR
Gabapentin monotherapy appears to be efficacious for the treatment of pain and sleep interference associated with diabetic peripheral neuropathy and exhibits positive effects on mood and quality of life. Expand
...
1
2
3
...